Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

Little pouches of nicotine sold by the brand ZYN were given the green light for marketing this week through the U.S. Food and ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...

Indianapolis-based Eli Lilly and Co. is projecting approval of its experimental weight-loss pill as soon as early 2026, CEO Dave Ricks said, one of several in a new generation of the popular drugs.

The U.S. Food and Drug Administration (FDA) recently approved ... Zepbound offers a new approach to managing OSA symptoms while also promoting significant weight loss. Zepbound is an injectable ...